TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced that a poster featuring its lead therapeutic candidate, TTX-MC138, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on Oct. 23 in Madrid, Spain. The presentation will highlight the latest clinical update from the Phase 1a trial evaluating TTX-MC138 in patients with advanced solid tumors.
The announcement is significant because it provides an independent forum for TransCode to share interim data on a first-in-class asset targeting miR-10b, a microRNA associated with metastatic disease progression. Metastatic disease remains the primary cause of cancer-related mortality, and therapies that specifically address the molecular drivers of metastasis are scarce. TTX-MC138 is designed to inhibit miR-10b, which is overexpressed in many aggressive tumors and is a well-documented biomarker of metastasis. A clinical update at ESMO, one of the largest global oncology meetings, could offer investors and clinicians greater visibility into the drug’s safety and early activity profile.
For TransCode, the ESMO presentation may serve as a catalyst for broader awareness among oncologists and potential partners. The company’s pipeline also includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. Positive or informative Phase 1a data could support the design of later-stage trials and help differentiate TTX-MC138 in a crowded immuno-oncology landscape. The full press release is available at https://nnw.fm/sGqsS.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://nnw.fm/RNAZ.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. These channels help emerging companies like TransCode reach a wide audience of investors and journalists. Full terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
